Nevirapine is the only nonnucleoside reverse transcriptase inhibitor currently available as a paediatric fixed-dose-combination tablet and is widely used in African children. Nonetheless, the number of investigations into pharmacokinetic determinants of virological suppression in African children is limited, and the predictive power of the current therapeutic range was never evaluated in this population, thereby limiting treatment optimization.
We analysed data from 322 African children (aged 0.3–13 years) treated with nevirapine, lamivudine, and either abacavir, stavudine, or zidovudine, and followed up to 144 weeks. Nevirapine trough concentration (C min) and other factors were tested for associations with viral load more than 100 copies/ml and transaminase increases more than grade 1 using proportional hazard and logistic models in 219 initially antiretroviral treatment (ART)-naive children.
Pre-ART viral load, adherence, and nevirapine C min were associated with viral load nonsuppression [hazard ratio = 2.08 (95% confidence interval (CI): 1.50–2.90, P < 0.001) for 10-fold higher pre-ART viral load, hazard ratio = 0.78 (95% CI: 0.68–0.90, P < 0.001) for 10% improvement in adherence, and hazard ratio = 0.94 (95% CI: 0.90–0.99, P = 0.014) for a 1 mg/l increase in nevirapine C min]. There were additional effects of pre-ART CD4+ cell percentage and clinical site. The risk of virological nonsuppression decreased with increasing nevirapine C min, and there was no clear C min threshold predictive of virological nonsuppression. Transient transaminase elevations more than grade 1 were associated with high C min (>12.4 mg/l), hazard ratio = 5.18 (95% CI 1.95–13.80, P < 0.001).
Treatment initiation at lower pre-ART viral load and higher pre-ART CD4+ cell percentage, increased adherence, and maintaining average C min higher than current target could improve virological suppression of African children treated with nevirapine without increasing toxicity.
Supplemental Digital Content is available in the text
aDivision of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa
bMRC Clinical Trials Unit at University College London, London, United Kingdom
cDepartment of Paediatrics and Child Health, University Teaching Hospital, Lusaka, Zambia
dJoint Clinical Research Centre
eBaylor College of Medicine Bristol Myers Squibb Children's Clinical Centre of Excellence, Kampala, Uganda
fGulu Regional Centre of Excellence, Gulu, Uganda
gDepartment of Pharmacy, Radboud University Medical Centre, Nijmegen, The Netherlands.
*Ann S. Walker and Helen McIlleron contributed equally to the article.
Correspondence to Helen McIlleron, PhD, Groote Schuur Hospital, Observatory, K45 Old Main Building, Cape Town 7925, South Africa. Tel: +27 21 406 6292; fax: +27 21 448 1989; e-mail: email@example.com
Received 14 October, 2016
Revised 5 December, 2016
Accepted 5 December, 2016
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website (http://www.AIDSonline.com).
This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0